uuid
stringlengths 4
8
| template_uuid
stringclasses 40
values | question
stringlengths 13
193
| answer
stringlengths 29
2.2k
| benchmark_query
stringlengths 138
627
| execution_results
stringlengths 2
1.14M
| query_type
stringclasses 2
values | sql_category
stringclasses 26
values | bio_category
stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q1.931
|
Q1
|
Is NCAM1 a druggable gene?
|
There are currently no approved drugs targeting NCAM1, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NCAM1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_189', 'drugName': 'Oncolysin S', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3306', 'drugName': 'Bb-10901', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.576
|
Q1
|
Is HCK a druggable gene?
|
There are currently 2 approved drugs which target HCK, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HCK %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3959', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4603', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4602', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4598', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3955', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4600', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3958', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3956', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4601', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3957', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4599', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2125', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6126', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6125', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2126', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2121', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2124', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6128', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6129', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2122', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6130', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6131', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6127', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2123', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1175', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1174', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1176', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1177', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4107', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4109', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4108', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.506
|
Q1
|
Is GABRG3 a druggable gene?
|
There are currently 66 approved drugs which target GABRG3, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GABRG3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1494', 'drugName': 'Thiopental', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2287', 'drugName': 'Clomethiazole', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5701', 'drugName': 'Triazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4453', 'drugName': 'Chlordiazepoxide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2275', 'drugName': 'Oxazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6282', 'drugName': 'Estazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4750', 'drugName': 'Clorazepic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2327', 'drugName': 'Pentobarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1496', 'drugName': 'Clonazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3142', 'drugName': 'Lorazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_314', 'drugName': 'Methohexital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1108', 'drugName': 'Temazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5114', 'drugName': 'Etomidate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5041', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4008', 'drugName': 'Midazolam Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2188', 'drugName': 'Midazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3115', 'drugName': 'Propofol', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5165', 'drugName': 'Thiamylal', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4253', 'drugName': 'Flumazenil', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5294', 'drugName': 'Eszopiclone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5981', 'drugName': 'Clobazam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2197', 'drugName': 'Methoxyflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1369', 'drugName': 'Ganaxolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6147', 'drugName': 'Clotiazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_422', 'drugName': 'Butabarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3050', 'drugName': 'Butabarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6371', 'drugName': 'Secobarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3265', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2854', 'drugName': 'Chlordiazepoxide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4143', 'drugName': 'Methohexital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3295', 'drugName': 'Ethchlorvynol', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_653', 'drugName': 'Flurazepam Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_757', 'drugName': 'Pentobarbital Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3020', 'drugName': 'Glutethimide', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4122', 'drugName': 'Halazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_215', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4830', 'drugName': 'Prazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_341', 'drugName': 'Metharbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1441', 'drugName': 'Methyprylon', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2585', 'drugName': 'Triclofos Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2623', 'drugName': 'Talbutal', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3021', 'drugName': 'Triclofos', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3421', 'drugName': 'Thiamylal Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1073', 'drugName': 'Primidone', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3415', 'drugName': 'Butalbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3979', 'drugName': 'Quazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1800', 'drugName': 'Remimazolam Besylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1332', 'drugName': 'Flunitrazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2025', 'drugName': 'Methaqualone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3278', 'drugName': 'Tetrazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4173', 'drugName': 'Methaqualone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2196', 'drugName': 'Methoxyflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_211', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3380', 'drugName': 'Remimazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_214', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5594', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5595', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5597', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5598', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5599', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5600', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3261', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3262', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3263', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3264', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_213', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3266', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3267', 'drugName': 'Desflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK10 (ENSG00000100433), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK2 (ENSG00000082482), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2918', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2919', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2920', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2921', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2922', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2923', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2924', 'drugName': 'Sevoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK18 (ENSG00000186795), KCNK3 (ENSG00000171303), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1046', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1047', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5037', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5038', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5039', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5040', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1074', 'drugName': 'Primidone', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5042', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5043', 'drugName': 'Halothane', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), KCNK10 (ENSG00000100433), KCNK3 (ENSG00000171303), KCNK18 (ENSG00000186795), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_210', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2509', 'drugName': 'Cenobamate', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2508', 'drugName': 'Cenobamate', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_164', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_163', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_216', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_212', 'drugName': 'Enflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK9 (ENSG00000169427), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK10 (ENSG00000100433)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2024', 'drugName': 'Brexanolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5271', 'drugName': 'Clorazepate Dipotassium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5596', 'drugName': 'Isoflurane', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNK10 (ENSG00000100433), KCNK9 (ENSG00000169427), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), KCNK3 (ENSG00000171303), KCNK2 (ENSG00000082482), GLRA1 (ENSG00000145888), GLRB (ENSG00000109738), KCNK18 (ENSG00000186795)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5547', 'drugName': 'Secobarbital', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4460', 'drugName': 'Alprazolam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4971', 'drugName': 'Thiopental Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6336', 'drugName': 'Flurazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_143', 'drugName': 'Meprobamate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1439', 'drugName': 'Diazepam', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.787
|
Q1
|
Is KEAP1 a druggable gene?
|
There are currently 3 approved drugs which target KEAP1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%KEAP1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3182', 'drugName': 'Dimethyl Fumarate', 'drugIsApproved': True, 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5578', 'drugName': 'Diroximel Fumarate', 'drugIsApproved': True, 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_313', 'drugName': 'Monomethyl Fumarate', 'drugIsApproved': True, 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4920', 'drugName': 'Bardoxolone Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'NFE2L2 (ENSG00000116044), KEAP1 (ENSG00000079999), PPARG (ENSG00000132170), IKBKB (ENSG00000104365)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4921', 'drugName': 'Bardoxolone Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'NFE2L2 (ENSG00000116044), KEAP1 (ENSG00000079999), PPARG (ENSG00000132170), IKBKB (ENSG00000104365)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4922', 'drugName': 'Bardoxolone Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'NFE2L2 (ENSG00000116044), KEAP1 (ENSG00000079999), PPARG (ENSG00000132170), IKBKB (ENSG00000104365)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.4
|
Q1
|
Is ABCB1 a druggable gene?
|
There are currently no approved drugs targeting ABCB1, but there are 5 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ABCB1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3894', 'drugName': 'Tariquidar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5486', 'drugName': 'Zosuquidar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3628', 'drugName': 'Valspodar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6233', 'drugName': 'Encequidar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5418', 'drugName': 'Biricodar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCC1 (ENSG00000103222), ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5419', 'drugName': 'Biricodar', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCC1 (ENSG00000103222), ABCB1 (ENSG00000085563)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1369
|
Q1
|
Is SLC34A2 a druggable gene?
|
There are currently no approved drugs targeting SLC34A2, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%SLC34A2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.469
|
Q1
|
Is FGR a druggable gene?
|
There is 1 drug, Dasatinib, that targets FGR, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%FGR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4602', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4601', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4599', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4598', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4600', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4603', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1177', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6126', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6130', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6129', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6125', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6128', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1175', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2125', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1176', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2123', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2126', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1174', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6131', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2122', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2121', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6127', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2124', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4107', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4108', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4109', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.323
|
Q1
|
Is CSF2RB a druggable gene?
|
There is 1 drug, Sargramostim, that targets CSF2RB, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CSF2RB %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5636', 'drugName': 'Sargramostim', 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF2RA (ENSG00000198223), CSF2RB (ENSG00000100368)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4751', 'drugName': 'Mavrilimumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2RA (ENSG00000198223), CSF2RB (ENSG00000100368)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1099', 'drugName': 'Cibinetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'EPOR (ENSG00000187266), CSF2RB (ENSG00000100368)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.6
|
Q1
|
Is ABCC8 a druggable gene?
|
There are currently 11 approved drugs which target ABCC8, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ABCC8 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_951', 'drugName': 'Chlorpropamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5473', 'drugName': 'Glimepiride', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2494', 'drugName': 'Repaglinide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5811', 'drugName': 'Nateglinide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1628', 'drugName': 'Glipizide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_427', 'drugName': 'Tolbutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2541', 'drugName': 'Gliclazide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3569', 'drugName': 'Tolbutamide Sodium, Sterile', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2335', 'drugName': 'Tolazamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_934', 'drugName': 'Glyburide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1234', 'drugName': 'Acetohexamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4657', 'drugName': 'Mitiglinide', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3288', 'drugName': 'Mitiglinide Calcium Dihydrate', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_679', 'drugName': 'Sarakalim', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431), ABCC8 (ENSG00000006071), KCNJ8 (ENSG00000121361)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_4992', 'drugName': 'Naminidil', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431), ABCC8 (ENSG00000006071), KCNJ8 (ENSG00000121361)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1003
|
Q1
|
Is NPY5R a druggable gene?
|
There are currently no approved drugs targeting NPY5R, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NPY5R %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_836', 'drugName': 'Mk-0557', 'drugIsApproved': False, 'newLinkedTargets_string': 'NPY5R (ENSG00000164129)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_848', 'drugName': 'Velneperit', 'drugIsApproved': False, 'newLinkedTargets_string': 'NPY5R (ENSG00000164129)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1770', 'drugName': 'S-237648', 'drugIsApproved': False, 'newLinkedTargets_string': 'NPY5R (ENSG00000164129)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.550
|
Q1
|
Is GRIN2B a druggable gene?
|
There are currently 14 approved drugs which target GRIN2B, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GRIN2B %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_70', 'drugName': 'Orphenadrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1959', 'drugName': 'Ketamine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_69', 'drugName': 'Orphenadrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6212', 'drugName': 'Orphenadrine Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4482', 'drugName': 'Esketamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1047', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4306', 'drugName': 'Orphenadrine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6209', 'drugName': 'Orphenadrine Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6210', 'drugName': 'Orphenadrine Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2915', 'drugName': 'Ketamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6211', 'drugName': 'Orphenadrine Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4308', 'drugName': 'Orphenadrine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_758', 'drugName': 'Felbamate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4307', 'drugName': 'Orphenadrine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_164', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4305', 'drugName': 'Orphenadrine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_769', 'drugName': 'Amantadine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4207', 'drugName': 'Amantadine', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4606', 'drugName': 'Memantine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1046', 'drugName': 'Acamprosate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_67', 'drugName': 'Orphenadrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_768', 'drugName': 'Amantadine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_817', 'drugName': 'Esketamine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_163', 'drugName': 'Acamprosate Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_68', 'drugName': 'Orphenadrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), HRH1 (ENSG00000196639), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2817', 'drugName': 'Memantine', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4206', 'drugName': 'Amantadine', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3009', 'drugName': 'Rapastinel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3404', 'drugName': 'Neramexane', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_743', 'drugName': 'Ralfinamide', 'drugIsApproved': False, 'newLinkedTargets_string': 'MAOB (ENSG00000069535), CACNA1B (ENSG00000148408), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3405', 'drugName': 'Neramexane', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_744', 'drugName': 'Ralfinamide', 'drugIsApproved': False, 'newLinkedTargets_string': 'MAOB (ENSG00000069535), CACNA1B (ENSG00000148408), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5794', 'drugName': 'Neramexane Mesylate', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5793', 'drugName': 'Neramexane Mesylate', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA9 (ENSG00000174343), CHRNA10 (ENSG00000129749), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_741', 'drugName': 'Ralfinamide', 'drugIsApproved': False, 'newLinkedTargets_string': 'MAOB (ENSG00000069535), CACNA1B (ENSG00000148408), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_742', 'drugName': 'Ralfinamide', 'drugIsApproved': False, 'newLinkedTargets_string': 'MAOB (ENSG00000069535), CACNA1B (ENSG00000148408), GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1129', 'drugName': 'Indantadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), MAOA (ENSG00000189221)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1000', 'drugName': 'Radiprodil', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2267', 'drugName': 'Rislenemdaz', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5926', 'drugName': 'Lanicemine', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3345', 'drugName': 'Evt-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4732', 'drugName': 'Av-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2903', 'drugName': 'Evt-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2523', 'drugName': 'Gw468816', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5517', 'drugName': 'Apimostinel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2572', 'drugName': 'Perzinfotel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3399', 'drugName': 'Traxoprodil', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3366', 'drugName': 'Neboglamine', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1128', 'drugName': 'Indantadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785), MAOA (ENSG00000189221)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3819', 'drugName': 'Azd8108', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2181', 'drugName': 'Cns-5161', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_5026', 'drugName': 'Delucemine', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1095
|
Q1
|
Is PLK1 a druggable gene?
|
There are currently no approved drugs targeting PLK1, but there are 8 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PLK1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2040', 'drugName': 'Volasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5804', 'drugName': 'Bi-2536', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6053', 'drugName': 'Onvansertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2668', 'drugName': 'Gsk-461364', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1404', 'drugName': 'Tak-960', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2649', 'drugName': 'Cafusertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3010', 'drugName': 'Hmn-214', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1861', 'drugName': 'Mk-1496', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.40
|
Q1
|
Is ADRB3 a druggable gene?
|
There are currently 27 approved drugs which target ADRB3, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ADRB3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3354', 'drugName': 'Carteolol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3364', 'drugName': 'Dilevalol Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_842', 'drugName': 'Dipivefrin', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2740', 'drugName': 'Isoproterenol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_907', 'drugName': 'Carvedilol Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5769', 'drugName': 'Isoproterenol Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1755', 'drugName': 'Carteolol Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6355', 'drugName': 'Dilevalol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2950', 'drugName': 'Hydroxyamphetamine Hydrobromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3365', 'drugName': 'Dilevalol Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1918', 'drugName': 'Hydroxyamphetamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1178', 'drugName': 'Mirabegron', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3793', 'drugName': 'Carvedilol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4285', 'drugName': 'Mephentermine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1843', 'drugName': 'Norepinephrine Bitartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_901', 'drugName': 'Epinephrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1742', 'drugName': 'Labetalol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5404', 'drugName': 'Labetalol Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4318', 'drugName': 'Droxidopa', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4865', 'drugName': 'Ephedrine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3892', 'drugName': 'Ephedrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1884', 'drugName': 'Epinephrine Bitartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5325', 'drugName': 'Ephedrine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1692', 'drugName': 'Dipivefrin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4567', 'drugName': 'Mephentermine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6354', 'drugName': 'Dilevalol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1992', 'drugName': 'Norepinephrine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_906', 'drugName': 'Carvedilol Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1200', 'drugName': 'Isoproterenol Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3794', 'drugName': 'Carvedilol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_9', 'drugName': 'Vibegron', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3401', 'drugName': 'Ritobegron', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1749', 'drugName': 'Amibegron Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2452', 'drugName': 'Amibegron', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5295', 'drugName': 'Solabegron', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2385', 'drugName': 'Rafabegron', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3729', 'drugName': 'Ly377604', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3730', 'drugName': 'Ly377604', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3731', 'drugName': 'Ly377604', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.545
|
Q1
|
Is GRIK3 a druggable gene?
|
There is 1 drug, Topiramate, that targets GRIK3, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GRIK3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1594', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1597', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1595', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1596', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1593', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1592', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5972', 'drugName': 'Selurampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5973', 'drugName': 'Selurampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3642', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4374', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3641', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4375', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.244
|
Q1
|
Is CDK4 a druggable gene?
|
There are currently 6 approved drugs which target CDK4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CDK4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3487', 'drugName': 'Ribociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3860', 'drugName': 'Trilaciclib Dihydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6006', 'drugName': 'Abemaciclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_170', 'drugName': 'Trilaciclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3488', 'drugName': 'Ribociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6007', 'drugName': 'Abemaciclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2093', 'drugName': 'Ribociclib Succinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_171', 'drugName': 'Trilaciclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2460', 'drugName': 'Palbociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3859', 'drugName': 'Trilaciclib Dihydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2092', 'drugName': 'Ribociclib Succinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK6 (ENSG00000105810)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2461', 'drugName': 'Palbociclib', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5625', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5626', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5624', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5621', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5622', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5623', 'drugName': 'Alvocidib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK7 (ENSG00000134058), CDK9 (ENSG00000136807), CDK6 (ENSG00000105810), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4661', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5841', 'drugName': 'Milciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4663', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5842', 'drugName': 'Milciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3344', 'drugName': 'Riviciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4373', 'drugName': 'Rg-547', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2272', 'drugName': 'At-7519', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5843', 'drugName': 'Milciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1429', 'drugName': 'Roniciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4658', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5844', 'drugName': 'Milciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK1 (ENSG00000170312), NTRK1 (ENSG00000198400), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4446', 'drugName': 'Voruciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4660', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4372', 'drugName': 'Rg-547', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4662', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3342', 'drugName': 'Riviciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3343', 'drugName': 'Riviciclib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4659', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4371', 'drugName': 'Rg-547', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1526', 'drugName': 'Ag-24322', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1722', 'drugName': 'Pha-793887', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1909', 'drugName': 'Azd-5438', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1527', 'drugName': 'Ag-24322', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5236', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5231', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1528', 'drugName': 'Ag-24322', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK1 (ENSG00000170312)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5232', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5233', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5234', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5235', 'drugName': 'Rgb-286638', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK9 (ENSG00000136807), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.138
|
Q1
|
Is CA5B a druggable gene?
|
There are currently 2 approved drugs which target CA5B, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CA5B %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6095', 'drugName': 'Sulthiame', 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267), CA7 (ENSG00000168748), CA1 (ENSG00000133742), CA3 (ENSG00000164879), CA6 (ENSG00000131686), CA12 (ENSG00000074410), CA14 (ENSG00000118298), CA9 (ENSG00000107159), CA4 (ENSG00000167434), CA13 (ENSG00000185015), CA5B (ENSG00000169239), CA5A (ENSG00000174990)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3089', 'drugName': 'Ethoxzolamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267), CA7 (ENSG00000168748), CA1 (ENSG00000133742), CA3 (ENSG00000164879), CA6 (ENSG00000131686), CA12 (ENSG00000074410), CA14 (ENSG00000118298), CA9 (ENSG00000107159), CA4 (ENSG00000167434), CA13 (ENSG00000185015), CA5B (ENSG00000169239), CA5A (ENSG00000174990)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1329
|
Q1
|
Is S1PR5 a druggable gene?
|
There are currently 3 approved drugs which target S1PR5, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%S1PR5 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5906', 'drugName': 'Fingolimod Lauryl Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4765', 'drugName': 'Fingolimod Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4817', 'drugName': 'Fingolimod', 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4816', 'drugName': 'Fingolimod', 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3780', 'drugName': 'Amiselimod', 'drugIsApproved': False, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6385', 'drugName': 'Amiselimod Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.623
|
Q1
|
Is HTR3A a druggable gene?
|
There are currently 21 approved drugs which target HTR3A, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HTR3A %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2172', 'drugName': 'Vortioxetine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2170', 'drugName': 'Vortioxetine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1377', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_777', 'drugName': 'Vortioxetine Hydrobromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_778', 'drugName': 'Vortioxetine Hydrobromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5894', 'drugName': 'Dolasetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3083', 'drugName': 'Tropisetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_893', 'drugName': 'Zimeldine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2386', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3577', 'drugName': 'Palonosetron Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6383', 'drugName': 'Zimeldine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4695', 'drugName': 'Ondansetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4889', 'drugName': 'Alosetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2936', 'drugName': 'Dolasetron Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5205', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2863', 'drugName': 'Dexfenfluramine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3506', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5986', 'drugName': 'Alosetron Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3504', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5203', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1378', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4389', 'drugName': 'Palonosetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2388', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2387', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2171', 'drugName': 'Vortioxetine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3505', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_776', 'drugName': 'Vortioxetine Hydrobromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3880', 'drugName': 'Dexfenfluramine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5204', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2107', 'drugName': 'Granisetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4955', 'drugName': 'Ondansetron Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_520', 'drugName': 'Granisetron Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2793', 'drugName': 'Ramosetron Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4079', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4176', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4175', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4080', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_220', 'drugName': 'Ramosetron', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3469', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3470', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3471', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4325', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3472', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3473', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3474', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3475', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_580', 'drugName': 'Pumosetrag', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2119', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2120', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4324', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1584', 'drugName': 'Cilansetron', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3B (ENSG00000149305)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.829
|
Q1
|
Is LRP1 a druggable gene?
|
There are currently no approved drugs targeting LRP1, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%LRP1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.699
|
Q1
|
Is IL4 a druggable gene?
|
There are currently no approved drugs targeting IL4, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IL4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5968', 'drugName': 'Pascolizumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL4 (ENSG00000113520)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_932', 'drugName': 'Romilkimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL4 (ENSG00000113520), IL13 (ENSG00000169194)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_933', 'drugName': 'Romilkimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL4 (ENSG00000113520), IL13 (ENSG00000169194)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1093
|
Q1
|
Is PLAT a druggable gene?
|
There is 1 drug, Aminocaproic Acid, that targets PLAT, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PLAT %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5590', 'drugName': 'Aminocaproic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'PLAT (ENSG00000104368), PLG (ENSG00000122194)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5591', 'drugName': 'Aminocaproic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'PLAT (ENSG00000104368), PLG (ENSG00000122194)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1474
|
Q1
|
Is TPH2 a druggable gene?
|
There are currently 3 approved drugs which target TPH2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TPH2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3468', 'drugName': 'Telotristat', 'drugIsApproved': True, 'newLinkedTargets_string': 'TPH2 (ENSG00000139287), TPH1 (ENSG00000129167)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1302', 'drugName': 'Telotristat Ethyl', 'drugIsApproved': True, 'newLinkedTargets_string': 'TPH2 (ENSG00000139287), TPH1 (ENSG00000129167)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1064', 'drugName': 'Telotristat Etiprate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TPH2 (ENSG00000139287), TPH1 (ENSG00000129167)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.585
|
Q1
|
Is HDAC4 a druggable gene?
|
There are currently 4 approved drugs which target HDAC4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HDAC4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4906', 'drugName': 'Panobinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6063', 'drugName': 'Romidepsin', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1601', 'drugName': 'Belinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5237', 'drugName': 'Panobinostat Lactate', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_296', 'drugName': 'Abexinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_685', 'drugName': 'Tacedinaline', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5058', 'drugName': 'Entinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_129', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3735', 'drugName': 'Quisinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_130', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_127', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_128', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5661', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5662', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5663', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1513
|
Q1
|
Is TYK2 a druggable gene?
|
There are currently 4 approved drugs which target TYK2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TYK2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6269', 'drugName': 'Deucravacitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1979', 'drugName': 'Deucravacitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4953', 'drugName': 'Tofacitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6268', 'drugName': 'Deucravacitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3515', 'drugName': 'Tofacitinib Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4653', 'drugName': 'Upadacitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_505', 'drugName': 'Delgocitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1942', 'drugName': 'Brepocitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4367', 'drugName': 'Peficitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1943', 'drugName': 'Brepocitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3073', 'drugName': 'Cerdulatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2274', 'drugName': 'Gusacitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3074', 'drugName': 'Cerdulatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2655', 'drugName': 'Nezulcitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2984', 'drugName': 'Ropsacitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6205', 'drugName': 'Izencitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3072', 'drugName': 'Cerdulatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2273', 'drugName': 'Gusacitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3075', 'drugName': 'Cerdulatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.815
|
Q1
|
Is LCK a druggable gene?
|
There are currently 3 approved drugs which target LCK, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%LCK %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4603', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5655', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4601', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_385', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4600', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_386', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_391', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5660', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5654', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5658', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_392', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4599', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5656', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_388', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5657', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5653', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4602', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_390', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4598', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5659', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_387', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_389', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1174', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1176', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1177', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2121', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2123', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2124', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6131', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2125', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6130', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1175', 'drugName': 'Ilorasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2126', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6125', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2122', 'drugName': 'Enmd-981693', 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6126', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6127', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6129', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6128', 'drugName': 'Tg100-801', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FGFR1 (ENSG00000077782), KDR (ENSG00000128052), FGFR2 (ENSG00000066468), EPHB4 (ENSG00000196411), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT1 (ENSG00000102755)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4062', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4063', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4065', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4069', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4070', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4066', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4064', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4067', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4107', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4108', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4068', 'drugName': 'Jnj-26483327', 'drugIsApproved': False, 'newLinkedTargets_string': 'SRC (ENSG00000197122), YES1 (ENSG00000176105), ERBB4 (ENSG00000178568), FYN (ENSG00000010810), FLT4 (ENSG00000037280), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), LYN (ENSG00000254087), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4109', 'drugName': 'Xl-228', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1463
|
Q1
|
Is TNNI2 a druggable gene?
|
There are currently no approved drugs targeting TNNI2, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TNNI2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_451', 'drugName': 'Reldesemtiv', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNNI2 (ENSG00000130598), TNNT3 (ENSG00000130595), TNNC2 (ENSG00000101470)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6283', 'drugName': 'Tirasemtiv', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNNI2 (ENSG00000130598), TNNT3 (ENSG00000130595), TNNC2 (ENSG00000101470)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.378
|
Q1
|
Is E2F1 a druggable gene?
|
There are currently no approved drugs targeting E2F1, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%E2F1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4614', 'drugName': 'Edifoligide Sodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'E2F1 (ENSG00000101412), E2F2 (ENSG00000007968), E2F3 (ENSG00000112242), E2F4 (ENSG00000205250), E2F5 (ENSG00000133740), E2F6 (ENSG00000169016), E2F7 (ENSG00000165891), E2F8 (ENSG00000129173)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1850', 'drugName': 'Edifoligide', 'drugIsApproved': False, 'newLinkedTargets_string': 'E2F1 (ENSG00000101412), E2F2 (ENSG00000007968), E2F3 (ENSG00000112242), E2F4 (ENSG00000205250), E2F5 (ENSG00000133740), E2F6 (ENSG00000169016), E2F7 (ENSG00000165891), E2F8 (ENSG00000129173)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.316
|
Q1
|
Is CREBBP a druggable gene?
|
There are currently no approved drugs targeting CREBBP, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CREBBP %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3141', 'drugName': 'Pri-724', 'drugIsApproved': False, 'newLinkedTargets_string': 'CREBBP (ENSG00000005339), CTNNB1 (ENSG00000168036)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.444
|
Q1
|
Is F8 a druggable gene?
|
There is 1 drug, Drotrecogin Alfa (Activated), that targets F8, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%F8 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2502', 'drugName': 'Drotrecogin Alfa (Activated)', 'drugIsApproved': True, 'newLinkedTargets_string': 'F8 (ENSG00000185010), F5 (ENSG00000198734)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2503', 'drugName': 'Drotrecogin Alfa (Activated)', 'drugIsApproved': True, 'newLinkedTargets_string': 'F8 (ENSG00000185010), F5 (ENSG00000198734)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6154', 'drugName': 'Octocog Alfa', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3304', 'drugName': 'Sgn-30', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4614', 'drugName': 'Edifoligide Sodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'E2F1 (ENSG00000101412), E2F2 (ENSG00000007968), E2F3 (ENSG00000112242), E2F4 (ENSG00000205250), E2F5 (ENSG00000133740), E2F6 (ENSG00000169016), E2F7 (ENSG00000165891), E2F8 (ENSG00000129173)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1977', 'drugName': 'Antihemophilic Factor, Human Recombinant', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2328', 'drugName': 'Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1259', 'drugName': 'Efmoroctocog Alfa', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4735', 'drugName': 'Giroctocogene Fitelparvovec', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3496', 'drugName': 'Omfiloctocog Alfa', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2241', 'drugName': 'Iratumumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_364', 'drugName': 'Tb-402', 'drugIsApproved': False, 'newLinkedTargets_string': 'F8 (ENSG00000185010)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5413', 'drugName': 'Hefi-1', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1850', 'drugName': 'Edifoligide', 'drugIsApproved': False, 'newLinkedTargets_string': 'E2F1 (ENSG00000101412), E2F2 (ENSG00000007968), E2F3 (ENSG00000112242), E2F4 (ENSG00000205250), E2F5 (ENSG00000133740), E2F6 (ENSG00000169016), E2F7 (ENSG00000165891), E2F8 (ENSG00000129173)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.321
|
Q1
|
Is CSF2 a druggable gene?
|
There are currently no approved drugs targeting CSF2, but there are 6 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CSF2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3438', 'drugName': 'Lenzilumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4644', 'drugName': 'Otilimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4178', 'drugName': 'Pexastimogene Devacirepvec', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_512', 'drugName': 'Plonmarlimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6254', 'drugName': 'Gimsilumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1335', 'drugName': 'Namilumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1186
|
Q1
|
Is PSMD8 a druggable gene?
|
There are currently 4 approved drugs which target PSMD8, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PSMD8 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_559', 'drugName': 'Bortezomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4407', 'drugName': 'Ixazomib Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2422', 'drugName': 'Carfilzomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3334', 'drugName': 'Ixazomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_969', 'drugName': 'Oprozomib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1317
|
Q1
|
Is RTN4 a druggable gene?
|
There are currently no approved drugs targeting RTN4, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RTN4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6319', 'drugName': 'Ozanezumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'RTN4 (ENSG00000115310)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5814', 'drugName': 'Atinumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'RTN4 (ENSG00000115310)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1158
|
Q1
|
Is PSMA8 a druggable gene?
|
There are currently 4 approved drugs which target PSMA8, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PSMA8 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3334', 'drugName': 'Ixazomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_559', 'drugName': 'Bortezomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2422', 'drugName': 'Carfilzomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4407', 'drugName': 'Ixazomib Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4687', 'drugName': 'Marizomib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_969', 'drugName': 'Oprozomib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.426
|
Q1
|
Is ERBB3 a druggable gene?
|
There is 1 drug, Vandetanib, that targets ERBB3, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ERBB3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1933', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1935', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1936', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1934', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1937', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1932', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1931', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2705', 'drugName': 'Patritumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3197', 'drugName': 'Poziotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1952', 'drugName': 'Patritumab Deruxtecan', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), TOP1 (ENSG00000198900)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1953', 'drugName': 'Patritumab Deruxtecan', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), TOP1 (ENSG00000198900)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3653', 'drugName': 'Amg-888', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3486', 'drugName': 'Duligotuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4692', 'drugName': 'Zenocutuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3203', 'drugName': 'Mm-111', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1385', 'drugName': 'Cdx-3379', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2504', 'drugName': 'Mm-121', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_28', 'drugName': 'Istiratumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4618', 'drugName': 'Sapitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4619', 'drugName': 'Sapitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4620', 'drugName': 'Sapitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3485', 'drugName': 'Duligotuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), EGFR (ENSG00000146648)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_29', 'drugName': 'Istiratumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), IGF1R (ENSG00000140443)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_418', 'drugName': 'Tarloxotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4106', 'drugName': 'Seribantumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3820', 'drugName': 'Lumretuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4339', 'drugName': 'Elgemtumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5199', 'drugName': 'Kbp5209', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1482', 'drugName': 'Av-203', 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.556
|
Q1
|
Is GRM3 a druggable gene?
|
There are currently no approved drugs targeting GRM3, but there are 4 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GRM3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6226', 'drugName': 'Pomaglumetad Methionil', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6227', 'drugName': 'Pomaglumetad Methionil', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6286', 'drugName': 'Decoglurant', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6287', 'drugName': 'Decoglurant', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_370', 'drugName': 'Ly404039', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1900', 'drugName': 'Ly2969822', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM3 (ENSG00000198822), GRM2 (ENSG00000164082)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_369', 'drugName': 'Ly404039', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM2 (ENSG00000164082), GRM3 (ENSG00000198822)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1899', 'drugName': 'Ly2969822', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM3 (ENSG00000198822), GRM2 (ENSG00000164082)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.598
|
Q1
|
Is HNF4A a druggable gene?
|
There is 1 drug, Alverine, that targets HNF4A, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HNF4A %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4846', 'drugName': 'Alverine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), HNF4A (ENSG00000101076)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4847', 'drugName': 'Alverine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), HNF4A (ENSG00000101076)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.922
|
Q1
|
Is MYH6 a druggable gene?
|
There is 1 drug, Mavacamten, that targets MYH6, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%MYH6 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1036', 'drugName': 'Mavacamten', 'drugIsApproved': True, 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1448', 'drugName': 'Omecamtiv Mecarbil', 'drugIsApproved': False, 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2405', 'drugName': 'Danicamtiv', 'drugIsApproved': False, 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.674
|
Q1
|
Is IL15 a druggable gene?
|
There are currently no approved drugs targeting IL15, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IL15 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3251', 'drugName': 'Ordesekimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL15 (ENSG00000164136)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1091
|
Q1
|
Is PLA2G5 a druggable gene?
|
There are currently no approved drugs targeting PLA2G5, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PLA2G5 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6244', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6245', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6246', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1248
|
Q1
|
Is RPL27A a druggable gene?
|
There is 1 drug, Ataluren, that targets RPL27A, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RPL27A %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3776', 'drugName': 'Ataluren', 'drugIsApproved': True, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4448', 'drugName': 'Elx-02', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2146', 'drugName': 'Dorlimomab Aritox', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_437', 'drugName': 'Cycloheximide', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1402
|
Q1
|
Is STAT3 a druggable gene?
|
There are currently no approved drugs targeting STAT3, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%STAT3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4959', 'drugName': 'Danvatirsen', 'drugIsApproved': False, 'newLinkedTargets_string': 'STAT3 (ENSG00000168610)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_199', 'drugName': 'Danvatirsen Sodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'STAT3 (ENSG00000168610)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.229
|
Q1
|
Is CDH3 a druggable gene?
|
There are currently no approved drugs targeting CDH3, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CDH3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1343', 'drugName': 'Pf-03732010', 'drugIsApproved': False, 'newLinkedTargets_string': 'CDH3 (ENSG00000062038)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1207
|
Q1
|
Is RAF1 a druggable gene?
|
There are currently 3 approved drugs which target RAF1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RAF1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_812', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1547', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1546', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_78', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_77', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_803', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1544', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_801', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_808', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1548', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_814', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_811', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_79', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1549', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_80', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_806', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_81', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_807', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_76', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_802', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_809', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_813', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_804', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1545', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_810', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_805', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_800', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_75', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1543', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4331', 'drugName': 'Tovorafenib', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764), ARAF (ENSG00000078061)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3694', 'drugName': 'Xl-281', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3033', 'drugName': 'Belvarafenib', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764), ARAF (ENSG00000078061)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3695', 'drugName': 'Xl-281', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2543', 'drugName': 'Lxh254', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4205', 'drugName': 'Rg-7376', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2835', 'drugName': 'Arq-736', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_125', 'drugName': 'Lgx-806', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5869', 'drugName': 'Ly-3009120', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), ARAF (ENSG00000078061), RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_126', 'drugName': 'Lgx-806', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5870', 'drugName': 'Ly-3009120', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), ARAF (ENSG00000078061), RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5871', 'drugName': 'Ly-3009120', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), ARAF (ENSG00000078061), RAF1 (ENSG00000132155)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2836', 'drugName': 'Arq-736', 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155), BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1198
|
Q1
|
Is PTGS2 a druggable gene?
|
There are currently 71 approved drugs which target PTGS2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PTGS2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2672', 'drugName': 'Parecoxib Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5955', 'drugName': 'Valdecoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5375', 'drugName': 'Bromfenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5116', 'drugName': 'Celecoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_988', 'drugName': 'Meloxicam', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4334', 'drugName': 'Dipyrone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3719', 'drugName': 'Aceclofenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4669', 'drugName': 'Oxyphenbutazone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1296', 'drugName': 'Balsalazide Disodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1392', 'drugName': 'Tolmetin Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3576', 'drugName': 'Benzydamine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1474', 'drugName': 'Benzydamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_579', 'drugName': 'Glafenine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2258', 'drugName': 'Ketorolac Tromethamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3122', 'drugName': 'Diclofenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1446', 'drugName': 'Dexibuprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5752', 'drugName': 'Lornoxicam', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1741', 'drugName': 'Etoricoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_354', 'drugName': 'Carprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_172', 'drugName': 'Oxyphenbutazone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3165', 'drugName': 'Indomethacin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3209', 'drugName': 'Ibuprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4517', 'drugName': 'Naproxen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4670', 'drugName': 'Fenoprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1078', 'drugName': 'Balsalazide', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3093', 'drugName': 'Fenoprofen Calcium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_737', 'drugName': 'Sulindac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5291', 'drugName': 'Naproxen Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4421', 'drugName': 'Phenylbutazone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_602', 'drugName': 'Diflunisal', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2069', 'drugName': 'Piroxicam', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5775', 'drugName': 'Flurbiprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5877', 'drugName': 'Ketoprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_148', 'drugName': 'Acetaminophen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2818', 'drugName': 'Diclofenac Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6049', 'drugName': 'Mesalamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4826', 'drugName': 'Ketorolac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5993', 'drugName': 'Parecoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5527', 'drugName': 'Tolmetin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1367', 'drugName': 'Bismuth Subsalicylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_989', 'drugName': 'Bromfenac Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5263', 'drugName': 'Diclofenac Potassium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3942', 'drugName': 'Rofecoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1563', 'drugName': 'Aspirin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3840', 'drugName': 'Acemetacin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3917', 'drugName': 'Apazone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1508', 'drugName': 'Fenclofenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4357', 'drugName': 'Indoprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4252', 'drugName': 'Indomethacin Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_792', 'drugName': 'Suprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2737', 'drugName': 'Flurbiprofen Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3630', 'drugName': 'Oxaprozin Potassium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4050', 'drugName': 'Ibuprofen Lysine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_566', 'drugName': 'Ibuprofen Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1802', 'drugName': 'Isoxicam', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3586', 'drugName': 'Ibufenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5380', 'drugName': 'Clometacin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4291', 'drugName': 'Olsalazine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5555', 'drugName': 'Nabumetone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1079', 'drugName': 'Balsalazide', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1298', 'drugName': 'Balsalazide Disodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3913', 'drugName': 'Olsalazine Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1077', 'drugName': 'Balsalazide', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3914', 'drugName': 'Olsalazine Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3015', 'drugName': 'Sulfasalazine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3016', 'drugName': 'Sulfasalazine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5034', 'drugName': 'Meclofenamic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5035', 'drugName': 'Meclofenamic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_146', 'drugName': 'Acetaminophen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_147', 'drugName': 'Acetaminophen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_916', 'drugName': 'Etodolac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6047', 'drugName': 'Mesalamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6048', 'drugName': 'Mesalamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4289', 'drugName': 'Olsalazine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4290', 'drugName': 'Olsalazine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1297', 'drugName': 'Balsalazide Disodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4018', 'drugName': 'Pirprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4888', 'drugName': 'Mefenamic Acid', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3087', 'drugName': 'Diclofenac Epolamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2747', 'drugName': 'Oxaprozin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5261', 'drugName': 'Nepafenac', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_229', 'drugName': 'Aloxiprin', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3915', 'drugName': 'Olsalazine Sodium', 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5314', 'drugName': 'Dexketoprofen', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2814', 'drugName': 'Dipyrone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_304', 'drugName': 'Lumiracoxib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1782', 'drugName': 'Naproxcinod', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5008', 'drugName': 'Esflurbiprofen', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1816', 'drugName': 'Polmacoxib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CA1 (ENSG00000133742), PTGS2 (ENSG00000073756), CA2 (ENSG00000104267)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3746', 'drugName': 'Gw-406381', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1817', 'drugName': 'Polmacoxib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CA1 (ENSG00000133742), PTGS2 (ENSG00000073756), CA2 (ENSG00000104267)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1818', 'drugName': 'Polmacoxib', 'drugIsApproved': False, 'newLinkedTargets_string': 'CA1 (ENSG00000133742), PTGS2 (ENSG00000073756), CA2 (ENSG00000104267)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2702', 'drugName': 'Loxoprofen', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5945', 'drugName': 'Iguratimod', 'drugIsApproved': False, 'newLinkedTargets_string': 'MIF (ENSG00000240972), TRAF3IP2 (ENSG00000056972), PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5946', 'drugName': 'Iguratimod', 'drugIsApproved': False, 'newLinkedTargets_string': 'MIF (ENSG00000240972), TRAF3IP2 (ENSG00000056972), PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5947', 'drugName': 'Iguratimod', 'drugIsApproved': False, 'newLinkedTargets_string': 'MIF (ENSG00000240972), TRAF3IP2 (ENSG00000056972), PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4452', 'drugName': 'Cimicoxib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5387', 'drugName': 'Naproxen Etemesil', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1154
|
Q1
|
Is PSMA4 a druggable gene?
|
There are currently 4 approved drugs which target PSMA4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PSMA4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3334', 'drugName': 'Ixazomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_559', 'drugName': 'Bortezomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2422', 'drugName': 'Carfilzomib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4407', 'drugName': 'Ixazomib Citrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4687', 'drugName': 'Marizomib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_969', 'drugName': 'Oprozomib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.712
|
Q1
|
Is INSR a druggable gene?
|
There are currently 37 approved drugs which target INSR, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%INSR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_495', 'drugName': 'Insulin Glargine', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5849', 'drugName': 'Insulin Susp Isophane Semisynthetic Purified Human', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4870', 'drugName': 'Insulin [Injection], Biphasic', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5559', 'drugName': 'Insulin Susp Protamine Zinc Purified Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_578', 'drugName': 'Insulin Lispro', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3637', 'drugName': 'Insulin Susp Protamine Zinc Purified Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_496', 'drugName': 'Insulin Zinc Susp Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1693', 'drugName': 'Insulin Susp Isophane Beef/Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2164', 'drugName': 'Insulin Susp Protamine Zinc Beef/Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1882', 'drugName': 'Insulin Purified Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5121', 'drugName': 'Insulin Lispro Protamine Recombinant', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2302', 'drugName': 'Insulin Purified Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5466', 'drugName': 'Insulin Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4915', 'drugName': 'Insulin Susp Isophane Recombinant Human', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4168', 'drugName': 'Insulin Detemir', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4804', 'drugName': 'Insulin Susp Isophane Purified Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5441', 'drugName': 'Insulin Glulisine', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_994', 'drugName': 'Insulin Zinc Susp Extended Purified Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1271', 'drugName': 'Insulin Zinc Susp Prompt Purified Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1883', 'drugName': 'Insulin Zinc Susp Extended Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2821', 'drugName': 'Insulin Zinc Susp Purified Beef/Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5848', 'drugName': 'Insulin Zinc Susp Semisynthetic Purified Human', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5348', 'drugName': 'Insulin Zinc Susp Recombinant Human', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4713', 'drugName': 'Insulin Zinc Susp Extended Recombinant Human', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1048', 'drugName': 'Insulin Aspart Protamine Recombinant', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2307', 'drugName': 'Insulin Zinc, Extended', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1233', 'drugName': 'Insulin Zinc Susp Purified Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3871', 'drugName': 'Insulin Zinc Susp Prompt Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3685', 'drugName': 'Insulin Degludec', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2549', 'drugName': 'Insulin', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6192', 'drugName': 'Insulin, Isophane', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3652', 'drugName': 'Insulin, Protamine Zinc', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4979', 'drugName': 'Insulin Aspart', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3610', 'drugName': 'Insulin Zinc, Prompt', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3326', 'drugName': 'Insulin Susp Isophane Purified Pork', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2997', 'drugName': 'Insulin Zinc Susp Purified Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5706', 'drugName': 'Insulin Susp Isophane Beef', 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4437', 'drugName': 'Insulin Human, Isophane', 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5323', 'drugName': 'Insulin Peglispro', 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4973', 'drugName': 'Linsitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4974', 'drugName': 'Linsitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_586', 'drugName': 'Insulin Tregopil', 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1288', 'drugName': 'Bms-754807', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1289', 'drugName': 'Bms-754807', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3066', 'drugName': 'Kw-2450', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3067', 'drugName': 'Kw-2450', 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.67
|
Q1
|
Is AOC3 a druggable gene?
|
There are currently no approved drugs targeting AOC3, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%AOC3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5390', 'drugName': 'Vepalimomab', 'drugIsApproved': False, 'newLinkedTargets_string': 'AOC3 (ENSG00000131471)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.395
|
Q1
|
Is EGLN2 a druggable gene?
|
There is 1 drug, Roxadustat, that targets EGLN2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%EGLN2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5393', 'drugName': 'Roxadustat', 'drugIsApproved': True, 'newLinkedTargets_string': 'EGLN2 (ENSG00000269858), P4HTM (ENSG00000178467), EGLN1 (ENSG00000135766), EGLN3 (ENSG00000129521)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2677', 'drugName': 'Daprodustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN2 (ENSG00000269858), P4HTM (ENSG00000178467), EGLN1 (ENSG00000135766), EGLN3 (ENSG00000129521)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5157', 'drugName': 'Vadadustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN3 (ENSG00000129521), EGLN1 (ENSG00000135766), EGLN2 (ENSG00000269858)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5155', 'drugName': 'Vadadustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN3 (ENSG00000129521), EGLN1 (ENSG00000135766), EGLN2 (ENSG00000269858)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5156', 'drugName': 'Vadadustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN3 (ENSG00000129521), EGLN1 (ENSG00000135766), EGLN2 (ENSG00000269858)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2680', 'drugName': 'Molidustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN2 (ENSG00000269858), EGLN1 (ENSG00000135766), EGLN3 (ENSG00000129521)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2679', 'drugName': 'Molidustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN2 (ENSG00000269858), EGLN1 (ENSG00000135766), EGLN3 (ENSG00000129521)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2681', 'drugName': 'Molidustat', 'drugIsApproved': False, 'newLinkedTargets_string': 'EGLN2 (ENSG00000269858), EGLN1 (ENSG00000135766), EGLN3 (ENSG00000129521)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.583
|
Q1
|
Is HDAC2 a druggable gene?
|
There are currently 5 approved drugs which target HDAC2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HDAC2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2373', 'drugName': 'Vorinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2372', 'drugName': 'Vorinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1601', 'drugName': 'Belinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4906', 'drugName': 'Panobinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2374', 'drugName': 'Vorinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6063', 'drugName': 'Romidepsin', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5237', 'drugName': 'Panobinostat Lactate', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2375', 'drugName': 'Vorinostat', 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_296', 'drugName': 'Abexinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5058', 'drugName': 'Entinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_685', 'drugName': 'Tacedinaline', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_128', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_94', 'drugName': 'Mocetinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC2 (ENSG00000196591), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_96', 'drugName': 'Mocetinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC2 (ENSG00000196591), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_130', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_127', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_93', 'drugName': 'Mocetinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC2 (ENSG00000196591), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_95', 'drugName': 'Mocetinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC2 (ENSG00000196591), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_97', 'drugName': 'Mocetinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC2 (ENSG00000196591), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_129', 'drugName': 'Fimepinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CB (ENSG00000051382), PIK3CD (ENSG00000171608), PIK3CA (ENSG00000121879), HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3735', 'drugName': 'Quisinostat', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5661', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5662', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5663', 'drugName': 'Cudc-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1019
|
Q1
|
Is OPRK1 a druggable gene?
|
There are currently 33 approved drugs which target OPRK1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%OPRK1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2630', 'drugName': 'Levallorphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_749', 'drugName': 'Butorphanol', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2492', 'drugName': 'Hydrocodone Polistirex', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2028', 'drugName': 'Buprenorphine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3500', 'drugName': 'Buprenorphine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2890', 'drugName': 'Samidorphan L-Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_705', 'drugName': 'Nalmefene Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4513', 'drugName': 'Hydrocodone', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3666', 'drugName': 'Codeine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1326', 'drugName': 'Nalbuphine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3927', 'drugName': 'Naloxone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4595', 'drugName': 'Anileridine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4938', 'drugName': 'Anileridine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_494', 'drugName': 'Codeine Polistirex', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5565', 'drugName': 'Levallorphan Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5566', 'drugName': 'Levallorphan Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1510', 'drugName': 'Dezocine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4534', 'drugName': 'Samidorphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2889', 'drugName': 'Samidorphan L-Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2029', 'drugName': 'Buprenorphine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4939', 'drugName': 'Anileridine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1554', 'drugName': 'Anileridine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1990', 'drugName': 'Codeine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2476', 'drugName': 'Hydrocodone Bitartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2629', 'drugName': 'Levallorphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4963', 'drugName': 'Codeine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3599', 'drugName': 'Oxymorphone', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2904', 'drugName': 'Dextromoramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5202', 'drugName': 'Naloxone', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1991', 'drugName': 'Nalbuphine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3607', 'drugName': 'Naltrexone', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3051', 'drugName': 'Naltrexone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4044', 'drugName': 'Nalmefene', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_529', 'drugName': 'Benzhydrocodone', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3008', 'drugName': 'Benzhydrocodone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4533', 'drugName': 'Samidorphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2891', 'drugName': 'Samidorphan L-Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3501', 'drugName': 'Buprenorphine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1672', 'drugName': 'Butorphanol Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1673', 'drugName': 'Butorphanol Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4408', 'drugName': 'Difelikefalin', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1553', 'drugName': 'Anileridine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4591', 'drugName': 'Oxymorphone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4594', 'drugName': 'Anileridine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4532', 'drugName': 'Samidorphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1511', 'drugName': 'Dezocine', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_750', 'drugName': 'Butorphanol', 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2658', 'drugName': 'Asimadoline', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4220', 'drugName': 'Nalfurafine', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5183', 'drugName': 'Cebranopadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRL1 (ENSG00000125510), OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5774', 'drugName': 'Nalfurafine Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_115', 'drugName': 'Aticaprant', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5184', 'drugName': 'Cebranopadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRL1 (ENSG00000125510), OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5108', 'drugName': 'Btrx-335140', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1459', 'drugName': 'Orp-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3884', 'drugName': 'Odelepran', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1458', 'drugName': 'Orp-101', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1313', 'drugName': 'Axomadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1314', 'drugName': 'Axomadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1315', 'drugName': 'Axomadol', 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRD1 (ENSG00000116329), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.213
|
Q1
|
Is CD3G a druggable gene?
|
There are currently 4 approved drugs which target CD3G, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CD3G %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3214', 'drugName': 'Muromonab-Cd3', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6103', 'drugName': 'Teclistamab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4607', 'drugName': 'Blinatumomab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), CD19 (ENSG00000177455)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4608', 'drugName': 'Blinatumomab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), CD19 (ENSG00000177455)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6102', 'drugName': 'Teclistamab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2538', 'drugName': 'Catumaxomab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), EPCAM (ENSG00000119888)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2537', 'drugName': 'Catumaxomab', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), EPCAM (ENSG00000119888)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5458', 'drugName': 'Elranatamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5924', 'drugName': 'Talquetamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPRC5D (ENSG00000111291), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3286', 'drugName': 'Mosunetuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1132', 'drugName': 'Epcoritamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5925', 'drugName': 'Talquetamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPRC5D (ENSG00000111291), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1358', 'drugName': 'Glofitamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1359', 'drugName': 'Glofitamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5457', 'drugName': 'Elranatamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3287', 'drugName': 'Mosunetuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1133', 'drugName': 'Epcoritamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1603', 'drugName': 'Odronextamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), MS4A1 (ENSG00000156738)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2317', 'drugName': 'Flotetuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), IL3RA (ENSG00000185291)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1602', 'drugName': 'Odronextamab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), MS4A1 (ENSG00000156738)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3153', 'drugName': 'Foralumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2316', 'drugName': 'Flotetuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), IL3RA (ENSG00000185291)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6251', 'drugName': 'Fbt-A05', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6250', 'drugName': 'Fbt-A05', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2967', 'drugName': 'Solitomab', 'drugIsApproved': False, 'newLinkedTargets_string': 'EPCAM (ENSG00000119888), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_2968', 'drugName': 'Solitomab', 'drugIsApproved': False, 'newLinkedTargets_string': 'EPCAM (ENSG00000119888), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_5274', 'drugName': 'Imc-Gp100', 'drugIsApproved': False, 'newLinkedTargets_string': 'PMEL (ENSG00000185664), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_5275', 'drugName': 'Imc-Gp100', 'drugIsApproved': False, 'newLinkedTargets_string': 'PMEL (ENSG00000185664), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1187
|
Q1
|
Is PTAFR a druggable gene?
|
There are currently no approved drugs targeting PTAFR, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PTAFR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2192', 'drugName': 'Rupatadine', 'drugIsApproved': False, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), PTAFR (ENSG00000169403)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2191', 'drugName': 'Rupatadine', 'drugIsApproved': False, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), PTAFR (ENSG00000169403)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2350', 'drugName': 'Minopafant', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTAFR (ENSG00000169403)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.957
|
Q1
|
Is NDUFB2 a druggable gene?
|
There are currently 2 approved drugs which target NDUFB2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NDUFB2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3900', 'drugName': 'Me-344', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2970', 'drugName': 'Nv-128', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.539
|
Q1
|
Is GRIA1 a druggable gene?
|
There are currently 2 approved drugs which target GRIA1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%GRIA1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1597', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2165', 'drugName': 'Perampanel', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1592', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1594', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1596', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1593', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1595', 'drugName': 'Topiramate', 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_375', 'drugName': 'Pesampator', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1143', 'drugName': 'Mibampator', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_967', 'drugName': 'Dasolampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4911', 'drugName': 'Zonampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_114', 'drugName': 'Farampator', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5646', 'drugName': 'Mk-8777', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5973', 'drugName': 'Selurampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6041', 'drugName': 'Cx1739', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5972', 'drugName': 'Selurampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3642', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3641', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2292', 'drugName': 'Tak-653', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4374', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4375', 'drugName': 'Tezampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3757', 'drugName': 'Talampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3758', 'drugName': 'Talampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_968', 'drugName': 'Dasolampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), GRIK1 (ENSG00000171189)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_782', 'drugName': 'Irampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_783', 'drugName': 'Irampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5797', 'drugName': 'Becampanel', 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1237
|
Q1
|
Is RPL17 a druggable gene?
|
There is 1 drug, Ataluren, that targets RPL17, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%RPL17 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3776', 'drugName': 'Ataluren', 'drugIsApproved': True, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4448', 'drugName': 'Elx-02', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738), RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2146', 'drugName': 'Dorlimomab Aritox', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_437', 'drugName': 'Cycloheximide', 'drugIsApproved': False, 'newLinkedTargets_string': 'RPSA (ENSG00000168028), RPS27 (ENSG00000177954), RPS6 (ENSG00000137154), RPS2 (ENSG00000140988), RPS3 (ENSG00000149273), RPS3A (ENSG00000145425), RPS4X (ENSG00000198034), RPS4Y1 (ENSG00000129824), RPS5 (ENSG00000083845), RPS7 (ENSG00000171863), RPS8 (ENSG00000142937), RPS9 (ENSG00000170889), RPS10 (ENSG00000124614), RPS11 (ENSG00000142534), RPS12 (ENSG00000112306), RPS13 (ENSG00000110700), RPS14 (ENSG00000164587), RPS15 (ENSG00000115268), RPS15A (ENSG00000134419), RPS16 (ENSG00000105193), RPS17 (ENSG00000182774), RPS18 (ENSG00000231500), RPS19 (ENSG00000105372), RPS20 (ENSG00000008988), RPS21 (ENSG00000171858), RPS23 (ENSG00000186468), RPS24 (ENSG00000138326), RPS25 (ENSG00000118181), RPS26 (ENSG00000197728), RPS27A (ENSG00000143947), RPS28 (ENSG00000233927), RPS29 (ENSG00000213741), FAU (ENSG00000149806), RPL3 (ENSG00000100316), RPL4 (ENSG00000174444), RPL5 (ENSG00000122406), RPL6 (ENSG00000089009), RPL7 (ENSG00000147604), RPL7A (ENSG00000148303), RPL8 (ENSG00000161016), RPL9 (ENSG00000163682), RPL10 (ENSG00000147403), RPL10A (ENSG00000198755), RPL11 (ENSG00000142676), RPL12 (ENSG00000197958), RPL13 (ENSG00000167526), RPL13A (ENSG00000142541), RPL14 (ENSG00000188846), RPL15 (ENSG00000174748), RPL17 (ENSG00000265681), RPL18 (ENSG00000063177), RPL18A (ENSG00000105640), RPL19 (ENSG00000108298), RPL21 (ENSG00000122026), RPL22 (ENSG00000116251), RPL23 (ENSG00000125691), RPL23A (ENSG00000198242), RPL24 (ENSG00000114391), RPL26 (ENSG00000161970), RPL27 (ENSG00000131469), RPL27A (ENSG00000166441), RPL28 (ENSG00000108107), RPL29 (ENSG00000162244), RPL30 (ENSG00000156482), RPL31 (ENSG00000071082), RPL32 (ENSG00000144713), RPL34 (ENSG00000109475), RPL35 (ENSG00000136942), RPL35A (ENSG00000182899), RPL36 (ENSG00000130255), RPL36A (ENSG00000241343), RPL37 (ENSG00000145592), RPL37A (ENSG00000197756), RPL38 (ENSG00000172809), RPL39 (ENSG00000198918), RPL41 (ENSG00000229117), RPLP0 (ENSG00000089157), RPLP1 (ENSG00000137818)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.685
|
Q1
|
Is IL1RAP a druggable gene?
|
There is 1 drug, Spesolimab, that targets IL1RAP, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IL1RAP %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2421', 'drugName': 'Spesolimab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1RL2 (ENSG00000115598), IL1RAP (ENSG00000196083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_102', 'drugName': 'Imsidolimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1RL2 (ENSG00000115598), IL1RAP (ENSG00000196083)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4120', 'drugName': 'Astegolimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1RAP (ENSG00000196083), IL1RL1 (ENSG00000115602)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.87
|
Q1
|
Is ATP2A1 a druggable gene?
|
There are currently no approved drugs targeting ATP2A1, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ATP2A1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3997', 'drugName': 'Mipsagargin', 'drugIsApproved': False, 'newLinkedTargets_string': 'ATP2A3 (ENSG00000074370), ATP2A1 (ENSG00000196296), ATP2A2 (ENSG00000174437)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1383
|
Q1
|
Is SMO a druggable gene?
|
There are currently 5 approved drugs which target SMO, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%SMO %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2876', 'drugName': 'Glasdegib Maleate', 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3933', 'drugName': 'Sonidegib Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5550', 'drugName': 'Vismodegib', 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1242', 'drugName': 'Glasdegib', 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3128', 'drugName': 'Sonidegib', 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6104', 'drugName': 'Patidegib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6003', 'drugName': 'Taladegib', 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1278', 'drugName': 'Bms-833923', 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_688', 'drugName': 'Leq506', 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3130', 'drugName': 'Tak-441', 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.274
|
Q1
|
Is CHRNB4 a druggable gene?
|
There are currently 6 approved drugs which target CHRNB4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CHRNB4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5467', 'drugName': 'Trimethaphan Camsylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4467', 'drugName': 'Trimethaphan', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_120', 'drugName': 'Mecamylamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1272', 'drugName': 'Mecamylamine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4468', 'drugName': 'Pentolinium Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4982', 'drugName': 'Pentolinium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6218', 'drugName': 'Larazotide', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1963', 'drugName': 'Larazotide Acetate', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2742', 'drugName': 'Simpinicline', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_23', 'drugName': 'Asm-024', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRNA7 (ENSG00000175344)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_27', 'drugName': 'Asm-024', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRNA7 (ENSG00000175344)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2741', 'drugName': 'Simpinicline', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_24', 'drugName': 'Asm-024', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRNA7 (ENSG00000175344)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_25', 'drugName': 'Asm-024', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRNA7 (ENSG00000175344)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_26', 'drugName': 'Asm-024', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644), CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539), CHRNA7 (ENSG00000175344)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.944
|
Q1
|
Is NDUFA5 a druggable gene?
|
There are currently 2 approved drugs which target NDUFA5, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NDUFA5 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3900', 'drugName': 'Me-344', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2970', 'drugName': 'Nv-128', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.684
|
Q1
|
Is IL1R1 a druggable gene?
|
There is 1 drug, Anakinra, that targets IL1R1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IL1R1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2379', 'drugName': 'Anakinra', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2001', 'drugName': 'Medi-8968', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_714', 'drugName': 'Amg-108', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1384
|
Q1
|
Is SNAP25 a druggable gene?
|
There are currently 6 approved drugs which target SNAP25, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%SNAP25 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2163', 'drugName': 'Onabotulinumtoxina', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5684', 'drugName': 'Abobotulinumtoxina', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3257', 'drugName': 'Botulinum Toxin Type A', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2511', 'drugName': 'Prabotulinumtoxin A', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4481', 'drugName': 'Daxibotulinumtoxina', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5795', 'drugName': 'Incobotulinumtoxina', 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2986', 'drugName': 'Trenibotulinumtoxine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.634
|
Q1
|
Is ICAM3 a druggable gene?
|
There are currently no approved drugs targeting ICAM3, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ICAM3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1930', 'drugName': 'Icm3', 'drugIsApproved': False, 'newLinkedTargets_string': 'ICAM3 (ENSG00000076662)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1053
|
Q1
|
Is PDE6A a druggable gene?
|
There are currently 2 approved drugs which target PDE6A, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PDE6A %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6107', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6106', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4264', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4263', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1435
|
Q1
|
Is TLR4 a druggable gene?
|
There are currently no approved drugs targeting TLR4, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TLR4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5358', 'drugName': 'Resatorvid', 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR4 (ENSG00000136869)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1063', 'drugName': 'Eritoran Tetrasodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR4 (ENSG00000136869), LY96 (ENSG00000154589)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_600', 'drugName': 'Eritoran', 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR4 (ENSG00000136869), LY96 (ENSG00000154589)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1058
|
Q1
|
Is PDE6H a druggable gene?
|
There are currently 2 approved drugs which target PDE6H, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PDE6H %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6107', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6106', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4264', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4263', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.275
|
Q1
|
Is CHRND a druggable gene?
|
There are currently 28 approved drugs which target CHRND, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CHRND %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2723', 'drugName': 'Succinylcholine Chloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_922', 'drugName': 'Decamethonium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2699', 'drugName': 'Metocurine Iodide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4182', 'drugName': 'Gallamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4392', 'drugName': 'Metocurine', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5170', 'drugName': 'Decamethonium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4801', 'drugName': 'Atracurium Besylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1165', 'drugName': 'Vecuronium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4193', 'drugName': 'Vecuronium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_544', 'drugName': 'Pipecuronium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5171', 'drugName': 'Pipecuronium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5531', 'drugName': 'Doxacurium Chloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3976', 'drugName': 'Mivacurium Chloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6073', 'drugName': 'Mivacurium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3167', 'drugName': 'Cisatracurium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3676', 'drugName': 'Cisatracurium Besylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5014', 'drugName': 'Rapacuronium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5464', 'drugName': 'Rapacuronium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5939', 'drugName': 'Atracurium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6111', 'drugName': 'Pancuronium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2796', 'drugName': 'Tubocurarine', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1958', 'drugName': 'Rocuronium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6206', 'drugName': 'Suxamethonium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4981', 'drugName': 'Doxacurium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4304', 'drugName': 'Gallamine Triethiodide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4096', 'drugName': 'Pancuronium', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5100', 'drugName': 'Tubocurarine Chloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3086', 'drugName': 'Rocuronium Bromide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.746
|
Q1
|
Is KCNC4 a druggable gene?
|
There are currently 5 approved drugs which target KCNC4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%KCNC4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5118', 'drugName': 'Guanidine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2190', 'drugName': 'Guanidine', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5420', 'drugName': 'Amifampridine', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1734', 'drugName': 'Dalfampridine', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3435', 'drugName': 'Amifampridine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5027', 'drugName': 'Tedisamil', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3950', 'drugName': 'Nerispirdine', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3951', 'drugName': 'Nerispirdine', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.364
|
Q1
|
Is DLL3 a druggable gene?
|
There are currently no approved drugs targeting DLL3, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%DLL3 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4409', 'drugName': 'Rovalpituzumab Tesirine', 'drugIsApproved': False, 'newLinkedTargets_string': 'DLL3 (ENSG00000090932)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.626
|
Q1
|
Is HTR3D a druggable gene?
|
There are currently 7 approved drugs which target HTR3D, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HTR3D %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2386', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3083', 'drugName': 'Tropisetron', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2388', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1378', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1377', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2387', 'drugName': 'Clothiapine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3880', 'drugName': 'Dexfenfluramine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2863', 'drugName': 'Dexfenfluramine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6383', 'drugName': 'Zimeldine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_893', 'drugName': 'Zimeldine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_220', 'drugName': 'Ramosetron', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2793', 'drugName': 'Ramosetron Hydrochloride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4080', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4175', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4079', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4176', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_580', 'drugName': 'Pumosetrag', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4325', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3469', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3470', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3471', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3472', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2119', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3473', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3474', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3475', 'drugName': 'Tedatioxetine', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), HTR2A (ENSG00000102468), ADRA1A (ENSG00000120907), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), SLC6A2 (ENSG00000103546), HTR2C (ENSG00000147246), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2120', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4324', 'drugName': 'Rg3487', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.3
|
Q1
|
Is ABCA1 a druggable gene?
|
There is 1 drug, Probucol, that targets ABCA1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ABCA1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_632', 'drugName': 'Probucol', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABCA1 (ENSG00000165029)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.7
|
Q1
|
Is ABCC9 a druggable gene?
|
There are currently 2 approved drugs which target ABCC9, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ABCC9 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1076', 'drugName': 'Pinacidil', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5958', 'drugName': 'Pinacidil', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5982', 'drugName': 'Minoxidil', 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_679', 'drugName': 'Sarakalim', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431), ABCC8 (ENSG00000006071), KCNJ8 (ENSG00000121361)', 'maxClinicalTrialPhase': -1}, {'UUID': 'DrugGeneTargets_v2_4992', 'drugName': 'Naminidil', 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431), ABCC8 (ENSG00000006071), KCNJ8 (ENSG00000121361)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.313
|
Q1
|
Is CPT2 a druggable gene?
|
There are currently 2 approved drugs which target CPT2, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CPT2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1726', 'drugName': 'Perhexiline Maleate', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_919', 'drugName': 'Perhexiline', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_918', 'drugName': 'Perhexiline', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1724', 'drugName': 'Perhexiline Maleate', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1725', 'drugName': 'Perhexiline Maleate', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_920', 'drugName': 'Perhexiline', 'drugIsApproved': True, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), CPT2 (ENSG00000157184), CPT1B (ENSG00000205560)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.717
|
Q1
|
Is ITGA4 a druggable gene?
|
There are currently 2 approved drugs which target ITGA4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ITGA4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5016', 'drugName': 'Natalizumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626), ITGB1 (ENSG00000150093)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5015', 'drugName': 'Natalizumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626), ITGB1 (ENSG00000150093)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5088', 'drugName': 'Vedolizumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3778', 'drugName': 'Abrilumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_786', 'drugName': 'Ucb-1184197', 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGA4 (ENSG00000115232)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2078', 'drugName': 'Firategrast', 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2077', 'drugName': 'Firategrast', 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA4 (ENSG00000115232), ITGB7 (ENSG00000139626)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.669
|
Q1
|
Is IL12A a druggable gene?
|
There is 1 drug, Ustekinumab, that targets IL12A, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IL12A %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3327', 'drugName': 'Ustekinumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3328', 'drugName': 'Ustekinumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_344', 'drugName': 'Ebdarokimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_345', 'drugName': 'Ebdarokimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1845', 'drugName': 'Briakinumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1844', 'drugName': 'Briakinumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.967
|
Q1
|
Is NDUFS1 a druggable gene?
|
There are currently 2 approved drugs which target NDUFS1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%NDUFS1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3900', 'drugName': 'Me-344', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2970', 'drugName': 'Nv-128', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1516
|
Q1
|
Is TYR a druggable gene?
|
There are currently 2 approved drugs which target TYR, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TYR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5010', 'drugName': 'Mequinol', 'drugIsApproved': True, 'newLinkedTargets_string': 'TYR (ENSG00000077498)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3683', 'drugName': 'Monobenzone', 'drugIsApproved': True, 'newLinkedTargets_string': 'TYR (ENSG00000077498)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1246', 'drugName': 'Arbutin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TYR (ENSG00000077498)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.217
|
Q1
|
Is CD44 a druggable gene?
|
There are currently no approved drugs targeting CD44, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CD44 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2202', 'drugName': 'Bivatuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2895', 'drugName': 'Pf-03475952', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508)', 'maxClinicalTrialPhase': -1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1460
|
Q1
|
Is TNKS2 a druggable gene?
|
There are currently no approved drugs targeting TNKS2, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%TNKS2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_1419', 'drugName': '2X-121', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNKS2 (ENSG00000107854), TNKS (ENSG00000173273), PARP1 (ENSG00000143799), PARP2 (ENSG00000129484)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1420', 'drugName': '2X-121', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNKS2 (ENSG00000107854), TNKS (ENSG00000173273), PARP1 (ENSG00000143799), PARP2 (ENSG00000129484)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1421', 'drugName': '2X-121', 'drugIsApproved': False, 'newLinkedTargets_string': 'TNKS2 (ENSG00000107854), TNKS (ENSG00000173273), PARP1 (ENSG00000143799), PARP2 (ENSG00000129484)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.28
|
Q1
|
Is ADORA1 a druggable gene?
|
There are currently 8 approved drugs which target ADORA1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ADORA1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4548', 'drugName': 'Theophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5470', 'drugName': 'Aminophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2662', 'drugName': 'Theophylline Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1105', 'drugName': 'Adenosine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2663', 'drugName': 'Theophylline Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4546', 'drugName': 'Theophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3798', 'drugName': 'Oxtriphylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5472', 'drugName': 'Aminophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_956', 'drugName': 'Theophylline Sodium Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4547', 'drugName': 'Theophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3799', 'drugName': 'Oxtriphylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2664', 'drugName': 'Theophylline Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_957', 'drugName': 'Theophylline Sodium Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5471', 'drugName': 'Aminophylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4744', 'drugName': 'Caffeine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3797', 'drugName': 'Oxtriphylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_955', 'drugName': 'Theophylline Sodium Glycinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6075', 'drugName': 'Caffeine, Citrated', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_448', 'drugName': 'Trabodenoson', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1264', 'drugName': 'Rolofylline', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1068', 'drugName': 'Tonapofylline', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_727', 'drugName': 'Amp579', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271), ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_728', 'drugName': 'Amp579', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271), ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2332', 'drugName': 'Derenofylline', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4405', 'drugName': 'Pbf-680', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3556', 'drugName': 'T-62', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6009', 'drugName': 'Bay1067197', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_275', 'drugName': 'Tecadenoson', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2152', 'drugName': 'Gw493838', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3660', 'drugName': 'Capadenoson', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1798', 'drugName': 'Naxifylline', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1822', 'drugName': 'Selodenoson', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_508', 'drugName': 'Fk453', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4180', 'drugName': 'Gs-9667', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5693', 'drugName': 'Rpr749', 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1105
|
Q1
|
Is POLD4 a druggable gene?
|
There are currently 5 approved drugs which target POLD4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%POLD4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4', 'drugName': 'Gemcitabine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4349', 'drugName': 'Cytarabine', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2785', 'drugName': 'Clofarabine', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2786', 'drugName': 'Clofarabine', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2916', 'drugName': 'Fludarabine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_66', 'drugName': 'Gemcitabine', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2917', 'drugName': 'Fludarabine Phosphate', 'drugIsApproved': True, 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_65', 'drugName': 'Gemcitabine', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5', 'drugName': 'Gemcitabine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3529', 'drugName': 'Aspacytarabine', 'drugIsApproved': False, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5766', 'drugName': 'Troxacitabine', 'drugIsApproved': False, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.894
|
Q1
|
Is MMP12 a druggable gene?
|
There are currently no approved drugs targeting MMP12, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%MMP12 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5864', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5863', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5862', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5861', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5859', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5860', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1157', 'drugName': 'Azd-1236', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1944', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1950', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1945', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1946', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1156', 'drugName': 'Azd-1236', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1947', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1948', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1949', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1071
|
Q1
|
Is PDPK1 a druggable gene?
|
There are currently no approved drugs targeting PDPK1, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PDPK1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4659', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4660', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4658', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4662', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4663', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4661', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_397', 'drugName': 'Ar-12', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.642
|
Q1
|
Is IFNA13 a druggable gene?
|
There are currently no approved drugs targeting IFNA13, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%IFNA13 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4431', 'drugName': 'Rontalizumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IFNA6 (ENSG00000120235), IFNA8 (ENSG00000120242), IFNA5 (ENSG00000147873), IFNA10 (ENSG00000186803), IFNA2 (ENSG00000188379), IFNA1 (ENSG00000197919), IFNA13 (ENSG00000233816), IFNA7 (ENSG00000214042), IFNA21 (ENSG00000137080), IFNA16 (ENSG00000147885), IFNA14 (ENSG00000228083), IFNA17 (ENSG00000234829), IFNA4 (ENSG00000236637)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5087', 'drugName': 'Sifalimumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IFNA6 (ENSG00000120235), IFNA8 (ENSG00000120242), IFNA5 (ENSG00000147873), IFNA10 (ENSG00000186803), IFNA2 (ENSG00000188379), IFNA1 (ENSG00000197919), IFNA13 (ENSG00000233816), IFNA7 (ENSG00000214042), IFNA21 (ENSG00000137080), IFNA16 (ENSG00000147885), IFNA14 (ENSG00000228083), IFNA17 (ENSG00000234829), IFNA4 (ENSG00000236637)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_928', 'drugName': 'Faralimomab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IFNA1 (ENSG00000197919), IFNA13 (ENSG00000233816)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.786
|
Q1
|
Is KDR a druggable gene?
|
There are currently 19 approved drugs which target KDR, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%KDR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_392', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_385', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3921', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1548', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3580', 'drugName': 'Cabozantinib S-Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3451', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5660', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1937', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5665', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4943', 'drugName': 'Axitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3919', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3918', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_77', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_386', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_811', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4523', 'drugName': 'Nintedanib Esylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3453', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6114', 'drugName': 'Lenvatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2106', 'drugName': 'Tivozanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3450', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1933', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_388', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5654', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5655', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_800', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5666', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3026', 'drugName': 'Lenvatinib Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_808', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_875', 'drugName': 'Tivozanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_806', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1543', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_810', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_75', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1544', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_78', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1549', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3922', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_387', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3923', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1932', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5928', 'drugName': 'Nintedanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4806', 'drugName': 'Cabozantinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3454', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_812', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4525', 'drugName': 'Nintedanib Esylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1936', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1935', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_81', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3449', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_80', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_79', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3920', 'drugName': 'Sunitinib Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_390', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_389', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5658', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5653', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5657', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_804', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5664', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5668', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5667', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_803', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_801', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2104', 'drugName': 'Tivozanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2105', 'drugName': 'Tivozanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_814', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_874', 'drugName': 'Tivozanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1547', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_876', 'drugName': 'Tivozanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_807', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3579', 'drugName': 'Cabozantinib S-Malate', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1545', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1934', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_813', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_76', 'drugName': 'Sorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_809', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1931', 'drugName': 'Vandetanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'TEK (ENSG00000120156), ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361), EPHA2 (ENSG00000142627), EPHB2 (ENSG00000133216), EPHA5 (ENSG00000145242), EPHA4 (ENSG00000116106), EPHA8 (ENSG00000070886), EPHA6 (ENSG00000080224), EPHA7 (ENSG00000135333), EPHB3 (ENSG00000182580), EPHA3 (ENSG00000044524), EPHB1 (ENSG00000154928), EPHB4 (ENSG00000196411), EPHA1 (ENSG00000146904), EPHB6 (ENSG00000106123), EPHA10 (ENSG00000183317), SRC (ENSG00000197122), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), PTK6 (ENSG00000101213)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_805', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5659', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_391', 'drugName': 'Pazopanib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5929', 'drugName': 'Nintedanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1170', 'drugName': 'Ramucirumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3452', 'drugName': 'Sunitinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), CSF1R (ENSG00000182578), FLT3 (ENSG00000122025), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5930', 'drugName': 'Nintedanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5656', 'drugName': 'Pazopanib', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_802', 'drugName': 'Regorafenib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1546', 'drugName': 'Sorafenib Tosylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4524', 'drugName': 'Nintedanib Esylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4807', 'drugName': 'Cabozantinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1790', 'drugName': 'Orantinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1453', 'drugName': 'Semaxanib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1811', 'drugName': 'Famitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), FLT3 (ENSG00000122025), KIT (ENSG00000157404), KDR (ENSG00000128052), FLT1 (ENSG00000102755), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6230', 'drugName': 'Surufatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6231', 'drugName': 'Surufatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1791', 'drugName': 'Orantinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1810', 'drugName': 'Famitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), FLT3 (ENSG00000122025), KIT (ENSG00000157404), KDR (ENSG00000128052), FLT1 (ENSG00000102755), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1260', 'drugName': 'Anlotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1261', 'drugName': 'Anlotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1809', 'drugName': 'Famitinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), FLT3 (ENSG00000122025), KIT (ENSG00000157404), KDR (ENSG00000128052), FLT1 (ENSG00000102755), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1262', 'drugName': 'Anlotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT4 (ENSG00000037280), KIT (ENSG00000157404), PDGFRB (ENSG00000113721), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.854
|
Q1
|
Is MAP3K5 a druggable gene?
|
There are currently no approved drugs targeting MAP3K5, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%MAP3K5 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5336', 'drugName': 'Selonsertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K5 (ENSG00000197442)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.628
|
Q1
|
Is HTR4 a druggable gene?
|
There are currently 13 approved drugs which target HTR4, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HTR4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_3506', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2042', 'drugName': 'Tegaserod Maleate', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5417', 'drugName': 'Clebopride', 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5204', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_893', 'drugName': 'Zimeldine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3505', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3176', 'drugName': 'Cisapride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4231', 'drugName': 'Tegaserod', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5203', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_110', 'drugName': 'Prucalopride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6383', 'drugName': 'Zimeldine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1378', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1377', 'drugName': 'Amisulpride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5416', 'drugName': 'Clebopride', 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2465', 'drugName': 'Prucalopride Succinate', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5205', 'drugName': 'Metoclopramide Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3504', 'drugName': 'Metoclopramide', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3880', 'drugName': 'Dexfenfluramine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2863', 'drugName': 'Dexfenfluramine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4176', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4079', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4080', 'drugName': 'Mosapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4175', 'drugName': 'Renzapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084), HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2305', 'drugName': 'Capeserod', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4024', 'drugName': 'Prx-03140', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4327', 'drugName': 'Felcisetrag', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3693', 'drugName': 'Relenopride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5450', 'drugName': 'Revexepride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_583', 'drugName': 'Naronapride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1938', 'drugName': 'Levosulpiride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_60', 'drugName': 'Piboserod', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_260', 'drugName': 'Velusetrag', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1939', 'drugName': 'Levosulpiride', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1043
|
Q1
|
Is PDE1B a druggable gene?
|
There are currently 2 approved drugs which target PDE1B, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PDE1B %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6107', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6106', 'drugName': 'Dipyridamole', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4264', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4263', 'drugName': 'Pentoxifylline', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2B (ENSG00000170425), ADORA2A (ENSG00000128271), PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.258
|
Q1
|
Is CHKA a druggable gene?
|
There are currently no approved drugs targeting CHKA, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CHKA %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6258', 'drugName': 'Tcd-717', 'drugIsApproved': False, 'newLinkedTargets_string': 'CHKA (ENSG00000110721)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.26
|
Q1
|
Is ADH7 a druggable gene?
|
There is 1 drug, Nitrefazole, that targets ADH7, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ADH7 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6344', 'drugName': 'Nitrefazole', 'drugIsApproved': True, 'newLinkedTargets_string': 'ADH1A (ENSG00000187758), ADH4 (ENSG00000198099), ADH1B (ENSG00000196616), ADH1C (ENSG00000248144), ADH7 (ENSG00000196344), ADH5 (ENSG00000197894), ADH6 (ENSG00000172955)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.338
|
Q1
|
Is CXCL8 a druggable gene?
|
There are currently no approved drugs targeting CXCL8, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CXCL8 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_4247', 'drugName': 'Humax-Il8', 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCL8 (ENSG00000169429)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4996', 'drugName': 'Abx-Il8', 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCL8 (ENSG00000169429)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.575
|
Q1
|
Is HCAR2 a druggable gene?
|
There are currently no approved drugs targeting HCAR2, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%HCAR2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5716', 'drugName': 'Sch-900271', 'drugIsApproved': False, 'newLinkedTargets_string': 'HCAR2 (ENSG00000182782)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.48
|
Q1
|
Is AKR1B1 a druggable gene?
|
There is 1 drug, Tolrestat, that targets AKR1B1, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%AKR1B1 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6334', 'drugName': 'Tolrestat', 'drugIsApproved': True, 'newLinkedTargets_string': 'AKR1B1 (ENSG00000085662)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2353', 'drugName': 'Sorbinil', 'drugIsApproved': False, 'newLinkedTargets_string': 'AKR1B1 (ENSG00000085662)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5553', 'drugName': 'Epalrestat', 'drugIsApproved': False, 'newLinkedTargets_string': 'AKR1B1 (ENSG00000085662)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6263', 'drugName': 'Caficrestat', 'drugIsApproved': False, 'newLinkedTargets_string': 'AKR1B1 (ENSG00000085662)', 'maxClinicalTrialPhase': 3}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.108
|
Q1
|
Is BCR a druggable gene?
|
There are currently 10 approved drugs which target BCR, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%BCR %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_6150', 'drugName': 'Ponatinib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2277', 'drugName': 'Ponatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2518', 'drugName': 'Imatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3412', 'drugName': 'Asciminib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4114', 'drugName': 'Asciminib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2515', 'drugName': 'Imatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2516', 'drugName': 'Imatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4600', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3269', 'drugName': 'Imatinib Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_436', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6061', 'drugName': 'Nilotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3955', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3956', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4601', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3958', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3959', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4598', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4599', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3271', 'drugName': 'Imatinib Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4602', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4603', 'drugName': 'Dasatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), KIT (ENSG00000157404), ABL1 (ENSG00000097007), BCR (ENSG00000186716), EPHA2 (ENSG00000142627)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2517', 'drugName': 'Imatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3413', 'drugName': 'Asciminib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3270', 'drugName': 'Imatinib Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3272', 'drugName': 'Imatinib Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3957', 'drugName': 'Bosutinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_435', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6060', 'drugName': 'Nilotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4219', 'drugName': 'Olverembatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1572', 'drugName': 'Radotinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5367', 'drugName': 'Vodobatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5368', 'drugName': 'Vodobatinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.351
|
Q1
|
Is CYP3A7 a druggable gene?
|
There are currently 2 approved drugs which target CYP3A7, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CYP3A7 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2751', 'drugName': 'Ritonavir', 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2752', 'drugName': 'Ritonavir', 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4493', 'drugName': 'Cobicistat', 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'maxClinicalTrialPhase': 4}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.56
|
Q1
|
Is ALK a druggable gene?
|
There are currently 7 approved drugs which target ALK, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%ALK %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_2435', 'drugName': 'Ceritinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1250', 'drugName': 'Alectinib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1249', 'drugName': 'Alectinib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1251', 'drugName': 'Alectinib Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2436', 'drugName': 'Ceritinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_237', 'drugName': 'Lorlatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1567', 'drugName': 'Brigatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1566', 'drugName': 'Brigatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1205', 'drugName': 'Entrectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2434', 'drugName': 'Ceritinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1203', 'drugName': 'Entrectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5880', 'drugName': 'Crizotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5878', 'drugName': 'Crizotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4673', 'drugName': 'Alectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5879', 'drugName': 'Crizotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4671', 'drugName': 'Alectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4672', 'drugName': 'Alectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1204', 'drugName': 'Entrectinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5881', 'drugName': 'Crizotinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_236', 'drugName': 'Lorlatinib', 'drugIsApproved': True, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6229', 'drugName': 'Ensartinib', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3702', 'drugName': 'Asp-3026', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4476', 'drugName': 'Cep-37440', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3235', 'drugName': 'Plb1003', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3236', 'drugName': 'Plb1003', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3029', 'drugName': 'Conteltinib ', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398), IGF1R (ENSG00000140443), PTK2B (ENSG00000120899)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3030', 'drugName': 'Conteltinib ', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398), IGF1R (ENSG00000140443), PTK2B (ENSG00000120899)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3031', 'drugName': 'Conteltinib ', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398), IGF1R (ENSG00000140443), PTK2B (ENSG00000120899)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3032', 'drugName': 'Conteltinib ', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398), IGF1R (ENSG00000140443), PTK2B (ENSG00000120899)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_4475', 'drugName': 'Cep-37440', 'drugIsApproved': False, 'newLinkedTargets_string': 'ALK (ENSG00000171094), PTK2 (ENSG00000169398)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.1136
|
Q1
|
Is PRKCD a druggable gene?
|
There is 1 drug, Midostaurin, that targets PRKCD, indicating that it is a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%PRKCD %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5668', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5664', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5665', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5666', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5667', 'drugName': 'Midostaurin', 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_940', 'drugName': 'Delcasertib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKCD (ENSG00000163932)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1322', 'drugName': 'Sotrastaurin', 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4663', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4660', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4658', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4662', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4659', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4661', 'drugName': 'Ucn-01', 'drugIsApproved': False, 'newLinkedTargets_string': 'PDPK1 (ENSG00000140992), CDK2 (ENSG00000123374), CDK4 (ENSG00000135446), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), CDK6 (ENSG00000105810), CHEK1 (ENSG00000149554)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3701', 'drugName': 'Cep-2563', 'drugIsApproved': False, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1835', 'drugName': 'Gsk-690693', 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKACB (ENSG00000142875), PRKACA (ENSG00000072062), PRKACG (ENSG00000165059), AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1837', 'drugName': 'Gsk-690693', 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKACB (ENSG00000142875), PRKACA (ENSG00000072062), PRKACG (ENSG00000165059), AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3697', 'drugName': 'Cep-2563', 'drugIsApproved': False, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3698', 'drugName': 'Cep-2563', 'drugIsApproved': False, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3699', 'drugName': 'Cep-2563', 'drugIsApproved': False, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3700', 'drugName': 'Cep-2563', 'drugIsApproved': False, 'newLinkedTargets_string': 'RET (ENSG00000165731), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1836', 'drugName': 'Gsk-690693', 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKACB (ENSG00000142875), PRKACA (ENSG00000072062), PRKACG (ENSG00000165059), AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.215
|
Q1
|
Is CD40 a druggable gene?
|
There are currently no approved drugs targeting CD40, but there are 11 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%CD40 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_507', 'drugName': 'Sotigalimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2640', 'drugName': 'Lucatumumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1904', 'drugName': 'Cdx-1140', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_506', 'drugName': 'Cd40 Ligand', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6028', 'drugName': 'Dacetuzumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3378', 'drugName': 'Bleselumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5569', 'drugName': 'Teneliximab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5276', 'drugName': 'Pg-102', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_834', 'drugName': 'Iscalimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2944', 'drugName': 'Giloralimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1342', 'drugName': 'Selicrelumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.122
|
Q1
|
Is BRD4 a druggable gene?
|
There are currently no approved drugs targeting BRD4, but there are 6 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%BRD4 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_866', 'drugName': 'Pelabresib', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_746', 'drugName': 'Apabetalone', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3995', 'drugName': 'Birabresib', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6242', 'drugName': 'Molibresib', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_569', 'drugName': 'Bms-986158', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1743', 'drugName': 'Ro-6870810', 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'maxClinicalTrialPhase': 1}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Q1.897
|
Q1
|
Is MMP2 a druggable gene?
|
There are currently no approved drugs targeting MMP2, but there are 3 drugs in clinical trials indicating that it may be a druggable gene.
|
SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE newLinkedTargets_string LIKE "%MMP2 %"
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100
|
[{'UUID': 'DrugGeneTargets_v2_5860', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5859', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5864', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5862', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5863', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5861', 'drugName': 'Marimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP3 (ENSG00000149968), MMP7 (ENSG00000137673), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245), MMP12 (ENSG00000262406)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1950', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1949', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1946', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_108', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1944', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1948', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_105', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_104', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_107', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1947', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_106', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_109', 'drugName': 'Rebimastat', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP14 (ENSG00000157227), MMP13 (ENSG00000137745), MMP9 (ENSG00000100985), MMP8 (ENSG00000118113), MMP1 (ENSG00000196611), MMP2 (ENSG00000087245)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1945', 'drugName': 'Cts-1027', 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP13 (ENSG00000137745), MMP8 (ENSG00000118113), MMP3 (ENSG00000149968), MMP2 (ENSG00000087245), MMP9 (ENSG00000100985), MMP12 (ENSG00000262406), MMP14 (ENSG00000157227)', 'maxClinicalTrialPhase': 2}]
|
general
|
Similarity Search, Order By, Distinct
|
Approval Status, Genetic Target
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.